Products Introduction

Unlocking the secrets of rarecells

MiCareo is pushing beyond thelimits of current liquid biopsy technologies by providing high purity isolatedlive rare cells and automated multiplexed fluorescence imaging. We are buildingtechnologies to accelerate the way pharmaceutical companies monitor drugresponse & screen for drug effectiveness, and giving researchers the toolsto find new correlations in biomarker expression using fully quantitativevisual subtyping of each cell.

Advantages

The MiSelect R achieves 90% cellrecovery with less than 10% variation.Best of all, users can confidently expect these results independent ofoperator experience level.

Furthermore, results thisimportant should not take days, or even weeks, to get back from a central lab.Process two samples of whole blood with only 10 minutes of hands on prep, andcomplete the automated imaging of rare target cells within a few hours, all inyour own lab.

This all-in-one device houses afully automated process from cell selection, to antibody labeling, tofluorescence imaging, which ensures that sample loss is minimized andresults are reproducible. Our gentle process and integrated instrument giveconsistent access to isolated live rare cells such as CTCs, and immune cells.

The MiSelect R is compactenough to fit on the corner of your workstation, making it a perfect fit forany lab, big or small.

Applications

Circulating Tumor Cells

The ability to monitor the level and type ofCTCs in a patient's blood provides rich information that is complementary anddistinct from all other current diagnostic information. The isolation andpurification of circulating tumor cells and the subsequent profiling of theirbiochemical changes, will greatly enhance both our understanding of cancer metastases,and in the assessment of experimental drugs/treatments.

Power of Enumeration

CTC enumeration has numerous potentialapplications include monitoring drug response/resistance, predicting theclinical outcome of cancer patients, or detecting potential metastasis early.However, CTC counts in cancer patients could be are incredibly low. 10 mLof blood may contain billions of RBCs, millions of leukocytes, and onlyone CTC.

Although detection, isolation, and analysisof CTCs has posed a challenge in the medical field, MiCareohas consistently achieved a 90% recovery efficiency with less than10% variation lab tests.

And unlike many CTC enumeration technologies,MiSelect preserves the integrity of isolated cells, affording accessto the complete range of genomic as well as cellular information.

Rare Immune Cells

Monitoring treatment efficacy is increasinglydifficult. Many checkpoint blockades are not found in tumor cells,but inhibitors are instead found acting upon immune cells suchas cytotoxic CD8(+) T cells. Profiling immune cells may give more completeinformation as to cell response or resistance to experimentaltreatments.